Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.

Autor: Shichi S; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Sugiyama K; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Asahi Y; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Shirakawa C; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Nakamoto H; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Kimura S; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Wakizaka K; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Aiyama T; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Nagatsu A; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Orimo T; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Kakisaka T; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Taketomi A; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7238.
DOI: 10.1002/cam4.7238
Abstrakt: Background: Intrahepatic cholangiocarcinoma (ICC) has a high recurrence rate and a poor prognosis. Thus, the development of effective treatment and prognostic biomarkers is required. High expression of diacylglycerol kinase alpha (DGKα) is a prognostic factor for the recurrence of hepatocellular carcinoma. However, the relationship between DGKα expression and prognosis in ICC has not been reported.
Methods: Immunohistochemistry (IHC) with anti-DGKα antibody was performed on surgical specimens of ICC (n = 69). First, DGKα expression in cancer cells was qualitatively classified into four groups (-, 1+, 2+, 3+) and divided into two groups (DGKα- and DGKα+1 + to 3+). The relationship between clinical features and DGKα expression was analyzed. Second, Ki-67 expression was evaluated as a cell proliferation marker. The number of Ki-67-positive cells was counted, and the relationship with DGKα expression was examined.
Results: DGKα IHC divided the patients into a DGKα+ group (1+: n = 15; 2+: n = 5; 3+: n = 5) and a DGKα- group (-: n = 44). In the DGKα+ group, patients were older and had advanced disease. Both overall survival and recurrence-free survival (RFS) were significantly worse in the DGKα+ patients. DGKα+ was identified as an independent prognostic factor for RFS by multivariate analysis. Furthermore, the number of Ki-67-positive cells increased in association with the staining levels of DGKα.
Conclusion: Pathological DGKα expression in ICC was a cancer proliferation marker associated with recurrence. This suggests that DGKα may be a potential therapeutic target for ICC.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje